Overall, our study reveals the molecular mechanism by which osteoblast‐secreted ECM1 in the bone microenvironment under anti‐androgen therapy pressure drives tumor resistance through the ECM1/ENO1/MAPK signaling axis in BMPC. The gene discussed is ENO1; the disease is neoplasm.